ライフサイエンスコーパス: ischemic cardiomyopathy

1 e therapeutic solutions to treat CVD such as ischemic cardiomyopathy.

2 ltered in failing human hearts and mice with ischemic cardiomyopathy.

3 are beneficial in a porcine model of chronic ischemic cardiomyopathy.

4 ving heart failure symptoms in patients with ischemic cardiomyopathy.

5 tegorized as Chagasic, other nonischemic, or ischemic cardiomyopathy.

6 nfirms the benefit of CABG for patients with ischemic cardiomyopathy.

7 ) patients affected by non-end stage dilated ischemic cardiomyopathy.

8 moderate long-term efficacy in patients with ischemic cardiomyopathy.

9 ion in animal models of both AMI and chronic ischemic cardiomyopathy.

10 in the hearts of controls and patients with ischemic cardiomyopathy.

11 tal prognostic value in patients with severe ischemic cardiomyopathy.

12 o long-term outcome in patients with chronic ischemic cardiomyopathy.

13 e to CRT both for dilated cardiomyopathy and ischemic cardiomyopathy.

14 n preserving ventricular function in porcine ischemic cardiomyopathy.

15 sults to a broad population of patients with ischemic cardiomyopathy.

16 rysm formation (e.g., sarcoidosis) may mimic ischemic cardiomyopathy.

17 nefit of bone marrow-derived hMSC in chronic ischemic cardiomyopathy.

18 plantable cardioverter defibrillator AND non-ischemic cardiomyopathy.

19 ous CPCs in patients with old MI and chronic ischemic cardiomyopathy.

20 he role of cardiac surgery for patients with ischemic cardiomyopathy.

21 tely reduces mitral regurgitation in porcine ischemic cardiomyopathy.

22 ary vessels and improve CBF in patients with ischemic cardiomyopathy.

23 ablished in a variety of aortic diseases and ischemic cardiomyopathy.

24 s after myocardial infarction and in chronic ischemic cardiomyopathy.

25 ue to reduce mitral regurgitation in porcine ischemic cardiomyopathy.

26 model of ischemic heart disease and in human ischemic cardiomyopathy.

27 entricular tachycardia (VT) in patients with ischemic cardiomyopathy.

28 progression of LV dysfunction in swine with ischemic cardiomyopathy.

29 dent predictor of mortality in patients with ischemic cardiomyopathy.

30 tality in primary-prevention candidates with ischemic cardiomyopathy.

31 a higher proportion of diabetes mellitus and ischemic cardiomyopathy.

32 se and arrhythmic mortality in patients with ischemic cardiomyopathy.

33 ) were 56 +/- 13 years and 71% male; 49% had ischemic cardiomyopathy.

34 dium and ameliorate heart failure in chronic ischemic cardiomyopathy.

35 is a treatment option for moderate-to-severe ischemic cardiomyopathy.

36 tribute to arrhythmic death in patients with ischemic cardiomyopathy.

37 failure (HF) and is a known risk factor for ischemic cardiomyopathy.

38 giogenesis offers the potential for treating ischemic cardiomyopathy.

39 an increase cardiac performance in rats with ischemic cardiomyopathy.

40 chemic myocardium in patients with end-stage ischemic cardiomyopathy.

41 by gene transfer of TIMP-1 in a rat model of ischemic cardiomyopathy.

42 d preserves cardiac function and geometry in ischemic cardiomyopathy.

43 ransfected with AdVEGF-165 in a rat model of ischemic cardiomyopathy.

44 ening appears to be limited to patients with ischemic cardiomyopathy.

45 ole for reactive O(2) in the pathogenesis of ischemic cardiomyopathy.

46 er nonischemic cardiomyopathy, and 1057 with ischemic cardiomyopathy.

47 ognostically powerful clinical definition of ischemic cardiomyopathy.

48 rapy for left ventricular dysfunction due to ischemic cardiomyopathy.

49 however, there is no uniform definition for ischemic cardiomyopathy.

50 gnificantly increased in human patients with ischemic cardiomyopathy.

51 hy, but remains impaired in those with prior ischemic cardiomyopathy.

52 ricular function in 27% of all patients with ischemic cardiomyopathy.

53 dial viability is important in patients with ischemic cardiomyopathy.

54 A usually present during infancy with severe ischemic cardiomyopathy.

55 ications for the management of patients with ischemic cardiomyopathy.

56 ic option in the management of patients with ischemic cardiomyopathy.

57 een in any of the samples from patients with ischemic cardiomyopathy.

58 pathic dilated cardiomyopathy, and three had ischemic cardiomyopathy.

59 nic disease states such as stable angina and ischemic cardiomyopathy.

60 assisted strategy in patients with suspected ischemic cardiomyopathy.

61 arrow cells into the hearts of patients with ischemic cardiomyopathy.

62 s scar size and improves cardiac function in ischemic cardiomyopathy.

63 d cardiac function in a preclinical model of ischemic cardiomyopathy.

64 l range, could provide protective effects in ischemic cardiomyopathy.

65 cells identically delivered in patients with ischemic cardiomyopathy.

66 D34(+) cell transplantation in patients with ischemic cardiomyopathy.

67 ts with nonischemic and 15% of patients with ischemic cardiomyopathy.

68 patients with nonischemic cardiomyopathy and ischemic cardiomyopathy.

69 nces left ventricular function in a model of ischemic cardiomyopathy.

70 with poor prognosis on the effect of CABG in ischemic cardiomyopathy.

71 elated with VA inducibility in patients with ischemic cardiomyopathy.

72 nd better exercise capacity in patients with ischemic cardiomyopathy.

73 ciated with VA inducibility in patients with ischemic cardiomyopathy.

74 m 15 subjects with hypertrophic, dilated, or ischemic cardiomyopathies.

75 year HR, 1.44; 3-year HR, 1.37; P<0.001) and ischemic cardiomyopathy (1-year HR, 1.39; 3-year HR, 1.4

76 including 5 normal controls, 4 subjects with ischemic cardiomyopathy, 1 with X-linked cardiomyopathy,

77 nic right ventricular cardiomyopathy than in ischemic cardiomyopathy (100% versus 86% versus 53%; P <

78 LAVAs were observed in 44 of 49 patients (15 ischemic cardiomyopathy, 15 nonischemic cardiomyopathy,

79 Among all patients (164 ischemic cardiomyopathy, 150 nonischemic dilated cardiom

80 Scarring was found in 100% of patients with ischemic cardiomyopathy (28 of 28) but in only 12% with

81 Of the 30 VTs, 24 (6 with ischemic cardiomyopathy, 3 with idiopathic cardiomyopath

82 on of AF in patients with nonischemic versus ischemic cardiomyopathy (41% versus 27%, P<0.005).

83 impaired in transplant recipients with prior ischemic cardiomyopathy (5.5 +/- 1.5%, p = 0.001 compare

84 edominantly white (85%) and male (72%), with ischemic cardiomyopathy (54%) and a pretransplant panel-

85 ion fraction (30% versus 38%), more frequent ischemic cardiomyopathy (58% versus 45%), more history o

86 n average age of 51 years, had predominately ischemic cardiomyopathy (63%), and a mean left ventricul

87 2 yr old) were included, most of them having ischemic cardiomyopathy (65.4%).

88 Of the 72 patients who were found to have ischemic cardiomyopathy, 71 patients had CC by EBCT (sen

89 mostly of white men (72%) and patients with ischemic cardiomyopathy (72%).

90 diabetes mellitus (36% versus 18%; P=0.045), ischemic cardiomyopathy (86% versus 52%; P=0.002), chron

91 +/-11.4 years, 82.1% were male, 42.5% had an ischemic cardiomyopathy, 87.7% were bridge to transplant

92 higher in nonischemic cardiomyopathy than in ischemic cardiomyopathy (93% versus 27%; P < 0.001).

93 ed with increased mortality in patients with ischemic cardiomyopathy (adjusted hazard ratio 1.33, 95%

94 case of a 71-year-old male with a history of ischemic cardiomyopathy after left ventricular assist de

95 ll-cause mortality in patients with advanced ischemic cardiomyopathy, after adjusting for clinical ri

96 ention plays a pivotal role in patients with ischemic cardiomyopathy, although these interventions ar

97 Precordial ECGs were recorded from 15 ischemic cardiomyopathy and 15 Brugada syndrome (type 1

98 ed, controlled trial involving patients with ischemic cardiomyopathy and an ICD who had ventricular t

99 In patients with ischemic cardiomyopathy and an ICD who had ventricular t

100 hmias by 3 months was 3% among patients with ischemic cardiomyopathy and congenital/inherited heart d

101 bypass grafting (CABG) for the patient with ischemic cardiomyopathy and congestive heart failure.

102 mic cardiomyopathy was limited to those with ischemic cardiomyopathy and diabetes mellitus (RR 1.37,

103 When patients with ischemic cardiomyopathy and diabetes mellitus were exclu

104 n identified patients within the cohort with ischemic cardiomyopathy and diabetes mellitus, with impr

105 y be particularly important in patients with ischemic cardiomyopathy and diabetes mellitus.

106 atients (81% male, age 62 +/- 13 years) with ischemic cardiomyopathy and ES underwent catheter ablati

107 In pathological conditions such as ischemic cardiomyopathy and heart failure, differentiati

108 eutic approach to prevent the progression of ischemic cardiomyopathy and heart failure.

109 therapies for prevalent conditions, such as ischemic cardiomyopathy and heart failure.

110 dial biopsies from patients with dilated and ischemic cardiomyopathy and in explanted hearts from pat

111 -controlled study involving 65 patients with ischemic cardiomyopathy and left ventricular (LV) ejecti

112 ine, male patients had a higher incidence of ischemic cardiomyopathy and longer QRS duration.

113 OMVP for MR in the setting of ischemic cardiomyopathy and low EF appear to improve ven

114 ppeared to be safe for patients with chronic ischemic cardiomyopathy and LV dysfunction.

115 Patients with ischemic cardiomyopathy and multiple VT were studied.

116 ous cardiovascular disease states, including ischemic cardiomyopathy and myocardial hibernation (5, 6

117 In patients with ischemic cardiomyopathy and no prior history of ventricu

118 over transthoracic echocardiography (TTE) in ischemic cardiomyopathy and nonischemic dilated cardiomy

119 on of cardiac AC(VI) expression in mice with ischemic cardiomyopathy and severe CHF improves function

120 ith reduced ejection fraction are those with ischemic cardiomyopathy and severe left ventricular syst

121 both post-acute myocardial infarction and in ischemic cardiomyopathy and that these effects are cause

122 Patients with ischemic cardiomyopathy and those with narrower QRS, in

123 t differ significantly between patients with ischemic cardiomyopathy and those with nonischemic cardi

124 n in a large cohort of patients with chronic ischemic cardiomyopathy and to determine the incremental

125 In 22 patients with ischemic cardiomyopathy and VT, high-density mapping was

126 rt failure in patients with dilated, but not ischemic, cardiomyopathy and to decrease strokes and arr

127 onischemic cardiomyopathy, 6 (4414 patients) ischemic cardiomyopathy, and 1 (2521 patients) both type

128 female, 10% LV ejection fraction </=25%, 55% ischemic cardiomyopathy, and 71% left bundle-branch bloc

129 ecial focus on cardiac magnetic resonance in ischemic cardiomyopathy, and provides an outlook on how

130 HIV infection, diabetes mellitus, history of ischemic cardiomyopathy, and undergoing percutaneous cor

131 more, in subjects with idiopathic dilated or ischemic cardiomyopathy, antiadrenergic therapy with bet

132 he setting of severe heart failure caused by ischemic cardiomyopathy are unknown.

133 ] trial) and establish this porcine model of ischemic cardiomyopathy as a useful and clinically relev

134 LGE-CMR was performed in 23 patients with ischemic cardiomyopathy before VT ablation.

135 travenous administration of TRH to rats with ischemic cardiomyopathy caused a significant increase in

136 ricular tissue from patients with dilated or ischemic cardiomyopathy compared to nonfailing donors.

137 The increased mortality in patients with ischemic cardiomyopathy compared with nonischemic cardio

138 increased more than 4-fold in the RVs of the ischemic cardiomyopathy compared with the nonfailing gro

139 n at subendocardium was lower in hearts with ischemic cardiomyopathy compared with those with nonisch

140 ays an important role in the pathogenesis of ischemic cardiomyopathy, contributing to systolic and di

141 Patients with established ischemic cardiomyopathy do not require electrophysiologi

142 o 1998 was performed comparing patients with ischemic cardiomyopathy (ejection fraction [EF] <25%) an

143 hymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist in chronic no

144 l biomarker able to predict the evolution of ischemic cardiomyopathy following revascularization.

145 of CAD and to develop the best definition of ischemic cardiomyopathy for prognostic purposes.

146 athy and from one of the three patients with ischemic cardiomyopathy had histochemical evidence of DN

147 evere mitral regurgitation in the setting of ischemic cardiomyopathy has been associated with poor su

148 tor of surgical revascularization benefit in ischemic cardiomyopathy has recently been questioned in

149 ow mononuclear cells (BMCs) in patients with ischemic cardiomyopathy have demonstrated safety and sug

150 Patients with ischemic cardiomyopathy have larger areas of abnormal in

151 Among patients with ischemic cardiomyopathy, hibernating, but not ischemic,

152 ovasculogenic myocardial repair in models of ischemic cardiomyopathy; however, these molecules have s

153 agnosed nonischemic cardiomyopathy (NICM) or ischemic cardiomyopathy (ICM) against sudden cardiac dea

154 cardioverter defibrillator (ICD) therapy in ischemic cardiomyopathy (ICM) and nonischemic cardiomyop

155 nts at higher risk of future events, both in ischemic cardiomyopathy (ICM) and nonischemic dilated ca

156 lar fibrillation (VF) storm in patients with ischemic cardiomyopathy (ICM) and the results of targete

157 butamine on left ventricular (LV) filling in ischemic cardiomyopathy (ICM) and to determine whether r

158 s with nonischemic cardiomyopathy (NICM) and ischemic cardiomyopathy (ICM) etiologies and evaluate th

159 erimental models; however, its role in human ischemic cardiomyopathy (ICM) has never been analysed.

160 eir native heart function, but the impact of ischemic cardiomyopathy (ICM) has not been specifically

161 ls examining the management of patients with ischemic cardiomyopathy (ICM) have questioned both the a

162 ion-related signaling in the pathogenesis of ischemic cardiomyopathy (ICM) in animal models, substant

163 cy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial.

164 leads to early improvement in LV function in ischemic cardiomyopathy (ICM) patients.

165 , respectively) as well as 161 patients with ischemic cardiomyopathy (ICM) undergoing CRT (n = 258) w

166 s with nonischemic cardiomyopathy (NICM) and ischemic cardiomyopathy (ICM), myocarditis patients were

167 In contrast, among 50 patients with ischemic cardiomyopathy (ICM), the heart weight index wa

168 (MSCs) are under evaluation as a therapy for ischemic cardiomyopathy (ICM).

169 nchronization therapy (CRT) in patients with ischemic cardiomyopathy (ICM).

170 cardiovascular events (CVE) in patients with ischemic cardiomyopathy (ICM).

171 ricular arrhythmias compared with those with ischemic cardiomyopathy (ICM).

172 le and nonviable myocardium in patients with ischemic cardiomyopathy (ICM).

173 n of VT in patients with NIDCM compared with ischemic cardiomyopathy (ICM).

174 (non-betaB-CHF) patients and in 4 subgroups: ischemic cardiomyopathy (ICM, n=10), nonischemic dilated

175 s with dilated cardiomyopathy (DCM, n=14) or ischemic cardiomyopathy (ICM, n=16) at the time of impla

176 NA from ventricular tissues of patients with ischemic cardiomyopathy (ICM, n=16) or idiopathic dilate

177 h significant mitral regurgitation caused by ischemic cardiomyopathy (ICM-MR) and by idiopathic dilat

178 s with chronic postinfarction heart failure (ischemic cardiomyopathy [ICM]).

179 Forty-six patients (18 ischemic cardiomyopathy [ICM], 13 nonischemic dilated ca

180 patients with end-stage heart failure due to ischemic cardiomyopathy (IHD) or dilated cardiomyopathy

181 In a transgenic model of ischemic cardiomyopathy in which monocytes are attracted

182 Severe mitral regurgitation in patients with ischemic cardiomyopathy increases the death rate and sym

183 In a mouse model of ischemic cardiomyopathy induced by repetitive ischemia/r

184 ngest associations observed in patients with ischemic cardiomyopathy (interaction P=0.008) and New Yo

185 e coronary artery bypass grafting in chronic ischemic cardiomyopathy is associated with substantially

186 cation of viable myocardium in patients with ischemic cardiomyopathy is considered important because

187 lear cells are safe and effective in chronic ischemic cardiomyopathy is controversial.

188 The pathophysiological substrate of ischemic cardiomyopathy is heterogeneous, varying from p

189 The long-term prognosis of patients with ischemic cardiomyopathy is highly variable, depending on

190 ery bypass grafting in patients with chronic ischemic cardiomyopathy is increasing in frequency, as i

191 efficacy of bypass surgery in patients with ischemic cardiomyopathy is not easily predictable; preop

192 Ischemic cardiomyopathy is the major cause of heart fail

193 Chronic left ventricular dysfunction in ischemic cardiomyopathy is the result of a mixture of sc

194 ED) in patients with heart failure caused by ischemic cardiomyopathy is the same in patients of diffe

195 alence of viable myocardium in patients with ischemic cardiomyopathy is unknown.

196 thic dilated cardiomyopathy (IDC; n = 31) or ischemic cardiomyopathy (ISC; n = 21) and membranes from

197 (control group), as well as 36 patients with ischemic cardiomyopathy (ischemic group).

198 A total of 362 patients with ischemic cardiomyopathy (left ventricular dysfunction wi

199 ed a prospective cohort of 768 patients with ischemic cardiomyopathy (left ventricular ejection fract

200 We enrolled 768 consecutive patients with ischemic cardiomyopathy (left ventricular ejection fract

201 York Heart Association functional class III ischemic cardiomyopathy (left ventricular ejection fract

202 ithout DM, those with DM had higher rates of ischemic cardiomyopathy, LVAD implantation as destinatio

203 rospective study that enrolled patients with ischemic cardiomyopathy (LVEF < or =0.40) and nonsustain

204 We prospectively enrolled 204 subjects with ischemic cardiomyopathy (LVEF </=35%) eligible for prima

205 Patients with ischemic cardiomyopathy may have a worse prognosis than

206 ss of functionally competent CSCs in chronic ischemic cardiomyopathy may underlie the progressive fun

207 s were included (mean age, 63; 95% male; 73% ischemic cardiomyopathy; mean left ventricular ejection

208 proved clinical status in some patients with ischemic cardiomyopathy, mild-to-moderate symptoms, narr

209 In an ischemic cardiomyopathy model, mice 4 weeks post-myocard

210 In the postinfarct ischemic cardiomyopathy model, VEGFR-1 deficiency suppor

211 by clinical factors, including advanced age, ischemic cardiomyopathy, more severe heart failure statu

212 to traditional indices such as low LVEF and ischemic cardiomyopathy, multivariable analysis showed t

213 nonischemic cardiomyopathy (n = 10) or prior ischemic cardiomyopathy (n = 10) and normal controls (n

214 Patients were considered to have ischemic cardiomyopathy (n = 3,112) if they had a histor

215 ither nonischemic cardiomyopathy (n = 10) or ischemic cardiomyopathy (n = 7), cardiac transplant reci

216 on (n=2), hypertrophic cardiomyopathy (n=1), ischemic cardiomyopathy (n=1), and arrhythmogenic right

217 diac causes was ascertained in subjects with ischemic cardiomyopathy (n=204) eligible for an implanta

218 re isolated from patients with CHF caused by ischemic cardiomyopathy (n=45) and healthy subjects (n=3

219 atients with dilated cardiomyopathy (n=5) or ischemic cardiomyopathy (n=5), were paced at 60 bpm.

220 anted hearts with either idiopathic (n=5) or ischemic cardiomyopathy (n=7) demonstrated substantial m

221 pathies associated with inflammation (n=27), ischemic cardiomyopathy (n=8), and the normal heart (n=1

222 Patients had ischemic cardiomyopathy (New York Heart Association [NYH

223 Seventeen subjects with ischemic cardiomyopathy, New York Heart Association clas

224 In Medicare patients, RBBB, ischemic cardiomyopathy, New York Heart Association clas

225 (statin) therapy on surrogate markers in non-ischemic cardiomyopathy (NICM) patients and average low-

226 In an animal model of ischemic cardiomyopathy, obliteration of a conductive is

227 nors and transplant recipients with endstage ischemic cardiomyopathy or idiopathic dilated cardiomyop

228 Patients with heart failure with either ischemic cardiomyopathy or nonischemic cardiomyopathy ha

229 e hundred fourteen consecutive patients with ischemic cardiomyopathy or nonischemic dilated cardiomyo

230 gical, and functional changes reminiscent of ischemic cardiomyopathy over time.

231 for AHR and RR in dilated cardiomyopathy and ischemic cardiomyopathy (p = 0.01 and p = 0.006) was see

232 rm survival was a pretransplant diagnosis of ischemic cardiomyopathy (p = 0.04).

233 Thirty patients with a history of ischemic cardiomyopathy participated in a phase I, nonra

234 human left ventricular tissue acquired from ischemic cardiomyopathy patients at cardiac transplantat

235 Analysis of shared frequency in ischemic cardiomyopathy patients with anteroseptal (n=4)

236 affected 40% of the inferior segments in all ischemic cardiomyopathy patients, whereas they affected

237 significantly increases freedom from VAs in ischemic cardiomyopathy patients.

238 patients with nonischemic cardiomyopathy and ischemic cardiomyopathy, patients with CCMP were overwhe

239 In ischemic cardiomyopathy, persistence of restrictive fill

240 In advanced ischemic cardiomyopathy, PI% is a powerful independent a

241 cute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies;

242 cute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies;

243 Ischemic cardiomyopathy predominated (65%), and 29% had

244 ional mitral regurgitation (MR) secondary to ischemic cardiomyopathy (prior bypass surgery in all cas

245 ears; LV ejection fraction, 30+/-6%; 18 with ischemic cardiomyopathy; QRS, 181+/-25 ms; all mean+/-SD

246 Patients with more advanced ischemic cardiomyopathy receive greater benefit from CAB

247 METHODS AND Thirty patients with ischemic cardiomyopathy received in a blinded manner eit

248 Finally, some patients with severe ischemic cardiomyopathy referred for cardiac transplanta

249 Thirty patients with ischemic cardiomyopathy referred for primary prevention

250 atients (all male; median age 60 years) with ischemic cardiomyopathy, refractory heart failure, and l

251 isk for all-cause mortality in patients with ischemic cardiomyopathy, (relative risk [RR] 1.37, 95% c

252 Interactions of age, sex, ischemic cardiomyopathy, renal failure, or QRS duration

253 tic or akinetic LV segments in patients with ischemic cardiomyopathy, requires accurate volume quanti

254 humans (Stem Cell Infusion in Patients with Ischemic CardiOmyopathy [SCIPIO] trial) and establish th

255 1 trial (Stem Cell Infusion in Patients with Ischemic cardiOmyopathy [SCIPIO]) of autologous CSCs for

256 ascular disease in patients transplanted for ischemic cardiomyopathy should exist.

257 rly VF in patients with Brugada syndrome and ischemic cardiomyopathy shows a predictable sequence in

258 needed to refine the clinical definition of ischemic cardiomyopathy so that physicians can appropria

259 In ischemic cardiomyopathy, sympathetic denervation assesse

260 A definition of ischemic cardiomyopathy that incorporated this definitio

261 In ischemic cardiomyopathy, the alpha 1-adrenergic receptor

262 In a cohort of patients with ischemic cardiomyopathy, the rates of death from any cau

263 In patients with ischemic cardiomyopathy, the reduced amount of viable my

264 modeling in mice with large infarcts, and in ischemic cardiomyopathy, they improve LV function, effec

265 ors of recovery included: age <50 years, non-ischemic cardiomyopathy, time from cardiac diagnosis <2

266 with 12 months of follow-up in subjects with ischemic cardiomyopathy to see if JVS-100 improves clini

267 RBBB and ischemic cardiomyopathy together had twice the adjusted

268 e left ventricular maps from 6 patients with ischemic cardiomyopathy (total 9 VTs) and were compared

269 In patients with severe ischemic cardiomyopathy treated with PCI, all-cause mort

270 The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)

271 dia Trial (MUSTT), the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)

272 olled in the DEFINITE (DEFIbrillators in Non-Ischemic cardiomyopathy Treatment Evaluation) study.

273 Forty patients with ischemic cardiomyopathy underwent (201)Tl scintigraphy (

274 Seventeen patients with known ischemic cardiomyopathy underwent dynamic (15)O-water an

275 We studied 54 patients with ischemic cardiomyopathy using rest and 4 h redistributio

276 ote increased vascular tissue in humans with ischemic cardiomyopathy via direct injection.

277 Ischemic cardiomyopathy was created in 10 additional swi

278 f patients in whom dilated cardiomyopathy or ischemic cardiomyopathy was diagnosed were examined for

279 Ischemic cardiomyopathy was more frequent in the HIV gro

280 evascularization in a group of patients with ischemic cardiomyopathy was performed.

281 In human hearts with end-stage ischemic cardiomyopathy, we find that BIN1 is also 50% r

282 ces of explanted hearts from 3 patients with ischemic cardiomyopathy were incubated in vitro with FBL

283 Lower rates of ischemic cardiomyopathy were observed (13% versus 41%; P

284 Gottingen swine with experimental ischemic cardiomyopathy were randomized to receive trans

285 e patients undergoing CRT (21 dilated and 12 ischemic cardiomyopathy) were studied.

286 predictor of poor outcomes in patients with ischemic cardiomyopathy; whether correcting it at the ti

287 tool for identifying high-risk patients with ischemic cardiomyopathy who are likely to benefit from i

288 erent mortality benefits among patients with ischemic cardiomyopathy who screen negative and non-nega

289 Fifteen consecutive patients with ischemic cardiomyopathy who underwent orthotopic cardiac

290 Subjects with ischemic cardiomyopathy who were scheduled for placement

291 Standardization of the definition of ischemic cardiomyopathy will be useful in the conduct an

292 highly effective therapy in the treatment of ischemic cardiomyopathy with excellent five-year outcome

293 rossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association

294 ctional recovery in a swine model of chronic ischemic cardiomyopathy without adverse immunologic reac

295 iary referral centers, 228 patients with non-ischemic cardiomyopathy without history of CHF were stud

296 In patients with non-ischemic cardiomyopathy without history of CHF, myocardi

297 of myocardial fibrosis in patients with non-ischemic cardiomyopathy without history of congestive he